Archives
Reporting Back on MDA’s First-Ever Virtual Hill Day
When the COVID-19 pandemic made meeting in person impossible, MDA’s Advocacy program needed to shift from in-person to virtual meetings with lawmakers. In early August, volunteers met with their lawmakers…
Who’s On Your MDA Care Center Team?: Young-Adult- and Adult-Focused Social Workers
At more than 150 MDA Care Centers nationwide, kids and adults living with neuromuscular disease (NMD) have access to multidisciplinary care teams made up of different specialists who can coordinate…
FDA Accepts Sarepta Therapeutics’ New Drug Application for DMD Treatment Casimersen
On Aug. 25, Sarepta Therapeutics announced that the US Food and Drug Administration (FDA) accepted the company’s New Drug Application (NDA) seeking accelerated approval for casimersen (SRP-4045), an investigational therapy…
Who’s On Your MDA Care Center Team?: Pediatric Social Workers
At more than 150 MDA Care Centers nationwide, kids and adults living with neuromuscular disease (NMD) have access to multidisciplinary care teams made up of different specialists who can coordinate…
Smashing Stereotypes
Jessica Hetzel faced a long but rewarding journey to join Greek life on her college campus. Making sorority life more inclusive, one chapter at a time
MDA’s 2020 Advocacy Agenda Update
Even during the COVID-19 pandemic, MDA continues to make sure lawmakers hear the voice of the neuromuscular disease community
The Expanding Therapeutic Landscape for Myasthenia Gravis
A Q&A with Gil I. Wolfe, MD
Expanding Access to Genetic Testing
MDA Care Centers bring no-cost genetic testing to people suspected of having a muscular dystrophy
Change for the Better
Advocacy for — and within — the neuromuscular disease community
FDA Approves NS Pharma’s Viltepso for Treatment of DMD Amenable to Exon 53 Skipping
Today, the US Food and Drug Administration (FDA) granted accelerated approval to viltolarsen (Viltepso) for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to skipping exon 53. It is…